Clinical Research Directory
Browse clinical research sites, groups, and studies.
MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment
Sponsor: Invitae Corporation
Summary
This study recruits patient with solid tumor types for sample collection and monitoring. Participants will provide blood and archival tissue samples in order to create a Personalized Cancer Monitoring (PCM) assay. This assay will be used to detect circulating tumor DNA (ctDNA) levels in the blood over time and hopefully contribute to improvements in residual disease detection methods for future patients. Results from this assay will be provided to participants and providers but providers are not asked to change patient care based on this information.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
400
Start Date
2021-11-29
Completion Date
2026-12
Last Updated
2024-03-12
Healthy Volunteers
No
Interventions
Personalized Cancer Monitoring (PCM)
personalized molecular test for solid tumor cancer patients that may detect the presence of circulating tumor DNA (ctDNA) and molecular residual disease (MRD), also known as minimal residual disease
Locations (2)
Columbus Regional Health
Columbus, Indiana, United States
Onslow Radiation
Jacksonville, North Carolina, United States